CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance in Mainland of China Yuelong Shu Chinese National Influenza Center National Institute.

Slides:



Advertisements
Similar presentations
Surveillance in a Pandemic: Situational Awareness
Advertisements

Influenza Surveillance
The 10th International Congress of the Asian Society of Clinical Pathology and Laboratory Medicine September 10-11, 2009 in Ulaanbaatar Mongolia.
H3N2 variant influenza A Maine, 2011 Sara Robinson, MPH Epidemiologist Maine Center for Disease Control and Prevention.
Integrated Epidemiological and Laboratory Surveillance and Reporting System in the NIC, Mongolia A.BURMAA, MD, MSc (Med), NIC, NCCD, Mongolia.
Characterization of human influenza virus circulation in Cambodia and impact for national public health policies. Ly Sovann, MD, DTMH, MCTM Philippe.
Public health assessment Avian flu A(H5N1) situation Feb 9, 2004.
Wrap-up of Day 1. Plenary One: Regional and Global Update Update of global situation and response to pandemic (H1N1) Dr Wenqing Zhang Regional.
Current AH1N1status and MoH Response Measure Sovann Ly, MD, DTMH, MCTM Deputy Director of CDC Department.
Global surveillance during pandemic Tim Nguyen Global Influenza Programme, WHO WHO updated interim recommendations.
Communicable Disease Surveillance & Response WHO-WPRO Pandemic (H1N1) 2009 situation and response in the Western Pacific Region Takeshi Kasai Communicable.
Challenges of the 2009 H1N1 Pandemic Influenza: Charles Penn Global Influenza Programme World Health Organization Geneva.
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)
National Influenza Sentinel Surveillance Viet Nam: US CDC Collaboration and WHO Global Surveillance Network Partnership Nguyen Thanh Chung, MD,
2012 Influenza A (H3N2)v Outbreak in Indiana: Highlighting Partnerships between Human and Animal Surveillance The Indiana State Department of Health (ISDH)
Ethics Conference on Asian Flu Pandemic Ethical considerations among Response to H1N1 Pandemic in China China CDC, CFETP Huilai Ma, Guang Zeng.
DR. JULIE LOUISE GERBERDING DIRECTOR CENTERS FOR DISEASE CONTROL AND PREVENTION CURRENT STATUS OF AVIAN INFLUENZA AND PANDEMIC THREAT PRESENTATION TO IOM,
Influenza Surveillance at IRID Immunization and Respiratory Infections Division Centre for Infectious Disease Prevention & Control Public Health Agency.
Infectious Disease Epidemiology Section Office of Public Health Louisiana Department of Health and Hospitals
Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.
Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.
Update on Influenza A(H5N1) Activity in Asia Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers for Disease Control.
Response to pandemic (H1N1) Country experience - Japan Tomimasa Sunagawa Infectious Disease Surveillance Center National Institute.
Update of Antiviral Resistance in Seasonal and Pandemic Influenza Viruses 3 rd NIC Meeting, Beijing, China August th 2009 Aeron Hurt WHO Collaborating.
Influenza A H1N1: A Pandemic in Real Time – What’s Next? Danny Chen, MD FRCPC MSc Infectious Disease Specialist Grand Rounds, York Central Hospital September.
Pandemic Responses & activities Sri Lanka. Activities initiated in Sri Lanka A Fact sheet (English pdf),(Sinhala pdf) has been prepared and distributed.
Centers for Disease Control and Prevention Program title: Developing sustainable surveillance and response for seasonal and avian influenza. Goal: To establish.
1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.
U.S. Influenza Surveillance Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.
Dr. Zhen XU Branch of Respiratory Disease Prevention and Control Division for Disease Control and Emergency Response Chinese Center for Disease Control.
Papua New Guinea Update 3 rd NIC Meeting 18 – 20 Beijing, China Berry Ropa National CSR Officer Department of Health Papua New Guinea.
World Health Organization, Regional Office for The Western Pacific Regional Activities Report and Preparation for the Upcoming Influenza Seasons THE 3rd.
Pandemic Response and current activities in Lao PDR NIC Meeting, Beijing, Aug 2009 Dr Phengta Vongphrachanh Director National centre for Laboratory.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.
Laboratory Integration in Influenza Surveillance Dr Geethani Wickramasinghe NIC- Sri Lanka.
US Situation Update and CDC International Response H1N1 Pandemic US Situation Update and CDC International Response Peter Nsubuga, MD, MPH On behalf of.
Pandemic H1N1 (2009) laboratory response Singapore.
1 Using ESSENCE-FL and a serosurvey to estimate total influenza infections, 2009 Richard S. Hopkins, MD, MSPH Kate Goodin, MPH Mackenzie Weise, MPH Aaron.
Manaaki Tangata Taiao Hoki protecting people and their environment through science Specialist Science Solutions NIC’s Pandemic influenza response and activities.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
Introduction for Basic Epidemiological Analysis for Surveillance Data National Center for Immunization & Respiratory Diseases Influenza Division.
1 Division of Health Security and Emergencies (DSE) WHO Western Pacific Regional Office (WPRO) Fifth Meeting of National Influenza Centres in the Western.
1 |1 | Situation Update Influenza A (H1N1), 26 May 09.
Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.
Wrap-up Day 2. Plenary Four: Pandemic and avian influenza updates Pandemic H1N1 – Origin of pandemic H1N1 virus – Genetically and antigenically homogenous.
THE DEVELOPMENT OF INFLUENZA SURVEILLANCE NETWORK IN THE PHILIPPINES (June 2005 – March 2008)‏ Remigio M. Olveda 1, Enrique A. Tayag 2, Analisa N. Bautista.
Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Novel influenza A (H1N1) Epidemiology Update Anthony Fiore, MD, MPH Influenza.
It’s Just Not the Flu Anymore Rick Hong, MD Associate Chairman CCHS EMC Medical Director, PHPS.
The New Influenza A/H1N1 Isabelle Thomas May 28-29, 2009 Brussels,
SAN DIEGO COUNTY INFLUENZA SURVEILLANCE October 14, 2015.
Influenza Surveillance in the United States Oliver Morgan, PhD MSc Division of Emerging Infections and Surveillance Services Dr. Lyn Finelli, Scott Epperson.
1 Influenza activity in the Southern Hemisphere Ian Barr WHO CC for Reference & Research on Influenza Melbourne The Melbourne WHO.
RCGP England: ‘influenza and influenza-like illness’
National Influenza Centres in SEA Region Dr Rajesh Bhatia / Dr Oommen John WHO Regional Office for South-East Asia New Delhi 5 th Meeting of NIC in Western.
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.
INFLUENZA DIVISION Update on the Epidemiology and Clinical Features of Novel H1N1 Joseph Bresee, MD Chief, Epidemiology and Prevention Branch Influenza.
DoD Global Influenza Surveillance Program Sentinel Site Surveillance at AFIOH Sequence Analysis And Vaccine Effectiveness Overview Luke T. Daum, PhD, Molecular.
Current situation and country response to Influenza A/H1N1 in Cambodia Ly Sovann, MD, DTMH, MCTM Deputy Director of CDC Department Ministry of Health,
Seoul Metropolitan Government Health & Welfare Headquarters Health Policy Division Kui-Nam Kim.
I Introduction to influenza
Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.
1. Globalization High Mobility of Human Globalization of infectious disease outbreaks Lessons from Pandemic (H1N1) 2009 Concern of next pandemic due to.
Establishment of Influenza Surveillance System in Liberia
The Role of NICs in Influenza Surveillance
A Web-based Interactive Genome Library for Surveillance, Detection, Characterization and Drug-Resistance Monitoring of Influenza Virus Infection in the.
J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y
Presentation transcript:

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance in Mainland of China Yuelong Shu Chinese National Influenza Center National Institute for Viral Disease Control and Prevention China CDC , Beijing

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Management of Influenza Surveillance Network in Mainland China Influenza Surveillance Data Response to Pandemic H1N1 2009

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Classification:  Seasonal Influenza: Class C Notifiable Infectious Disease  Pandemic A(H1N1) 2009 : Class B Notifiable Infectious Disease  H5N1: Class B Notifiable Infectious Disease Sentinel hospital-based surveillance:  ILI surveillance  Virological surveillance Influenza or ILI outbreak surveillance:  Outbreak report  Virological surveillance Influenza Surveillance in Mainland China

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION To monitor influenza activity in mainland China To monitor the antigenic and genetic characterization of influenza virus: for recommendation of representative strain and vaccine strain To monitor reassortant or mutation of the virus: more severe or/and transmissible? Drug resistance surveillance To monitor the novel influenza virus 4 Surveillance Objectives

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION 5 History Influenza research initiated in 1952 in mainland of China Influenza department of Institute of Virology was established in 1954 Chinese National Influenza Center was established in 1957 Rejoined WHO Global influenza surveillance network (GISN) in 1981

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Structure of National Influenza Surveillance Network(NISN)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION 63 network laboratories and 197 sentinel hospitals since Oct, 2005

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION 411 network laboratories and 556 sentinel hospitals since June, 2009

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Network Laboratories Samples Collection Fill the Original Form For Delivery and Examination Fill the Original Form For Delivery and Examination Sentinel Hospitals CNIC Samples Identification Print the Delivery and Examination Form of Flu Virus Strain Print the Delivery and Examination Form of Flu Virus Strain Confirmation & Feedback Confirmation & Feedback Lab Results Entry ILI Report Updated Surveillance Information System for Influenza China Information System for Disease Control and Prevention Surveillance Information System for Influenza Information Management System for A (H1N1)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance Information System (continued) ILI report by sentinel hospitals Virological Surveillance Virological Surveillance

Influenza Surveillance Information System (3) No. of consultations ILI by age groups

Influenza Surveillance Information System (4) Patient’s Information Patient’s Information Specimen’s Information Specimen’s Information Laboratory Information Laboratory Information

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance Information System (5) PCR Test for novel A(H1N1) 2009

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Accelerating national and international cooperation and communication and continuing participation in the GISN English Weekly Report

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Virus Database Add Search Sequence Database Add Search Download Multi-alignment & BLAST Developing Virus Information Database for NISN 15

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Identification and confirmation of influenza virus in CNIC

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Number of virus isolates sequenced in CNIC

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION

Trainings to the NISN 19 Every year CNIC organizes various training courses for the NISN, such as epidemiology workshop, laboratory detection techniuqe training, Biosafety training, GLP training and laboratory hands on training, etc. More than 2000 epidemiologists and laboratory technicians were trained in the last five years.

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Supervision Supervision have been organized each year since 2000.

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION National Influenza Surveillance Quality Evaluation System To strengthen the management of the NISN. The evaluation system includes the following 4 parts:  Virological Surveillance  Epidemiological Surveillance  Outbreak Surveillance  Management of the Network Laboratory The Quality Evaluation includes about 20 indicators.

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Quality Evaluation to the National Influenza Surveillance System The Quality Evaluation results

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION International Cooperation & Communication

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION International Cooperation & Communication Tabletop Exercise Symposium

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Surveillance Data

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Percentage of ILI Reported by Sentinel Hospitals during 2006 - 2009 in Southern Area

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Percentage of ILI Reported by Sentinel Hospitals during 2006 - 2009 in Northern Area

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION H3 dominant H1 dominant H3 dominant

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Composition of the type/subtype of influenza virus since June1 st,2009

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION *≥8 fold lower in HI titer Seasonal Influenza A(H1N1)NO.Percent WHO recommended Vaccine strain (2008/09North- 2009/10 North) In total 1400 isolates A/Brisbane/59/2007-like % A/Brisbane/59/2007-low* % WHO recommended Vaccine strain (2007/08North- 2008South) In total 1400 isolates A/Solomon islands/3/2006-like % A/Solomon islands/3/2006-low* % China Recommended Epidemic Reference Strain for Network labs (2008 Oct-2009 Sept) In total 1400 isolates A/Guangdong-baoan/51/2008- like % A/Guangdong-baoan/51/2008- low* % China Recommended Epidemic Reference Strain for Network labs (2009 Oct-2010 Sept) In total 802 isolates A/Tianjin-jinnan/15/2009-like % A/Tianjin-jinnan/15/2009-low* 496.1% Antigenic Analysis of Seasonal H1N1 –Tested at CNIC (Jan, 2009-July, 2009) (Chicken Antiserum)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION *≥8 fold lower in HI titer A(H3N2)NO.Percent WHO recommended Vaccine strain (2008South-2009/10 North) In total 396 isolates A/Brisbane/10/2007-like % A/Brisbane/10/2007-low* % WHO recommended Vaccine strain (2006/07North- 2007/08North) In total 396 isolates A/Wisconsin/67/2005-like 287.1% A/Wisconsin/67/2005 -low* % China Recommended Epidemic Reference Strain for Network labs (2007 Oct-2008 Sept) In total 399 isolates A/Jiangxi-donghu/312/2006-like % A/Jiangxi-donghu/312/2006-low* % China Recommended Epidemic Reference Strain for Network labs (2008 Oct-2009 Sept) In total 399 isolates A/Anhui-baohe/137/2008-like % A/Anhui-baohe/137/2008-low* % China Recommended Epidemic Reference Strain for Network labs (2009 Oct-2010 Sept) In total 75 isolates A/Fujian-tongan/196/2009-like % A/Fujian-tongan/196/2009-low* % Antigenic Analysis of H3N2 –Tested at CNIC (Jan, 2009-July, 2009) (Chicken Antiserum)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION *≥8 fold lower in HI titer B(Victoria)NO.Percent WHO recommended Vaccine strain (2009South- ) In total 56 isolates(with Ferret Antiserum) BV/Brisbane/60/2008-like % BV/Brisbane/60/2008-low* % WHO recommended Vaccine strain (2006South-2007/8 North) In total 1292 isolates(with Chicken Antiserum) B/Malaysia/2506/2004-like 685.3% B/Malaysia/2506/2004-low* % China Recommended Epidemic Reference Strain for Network labs (2008 Oct-2009 Sept) In total 1343 isolates(with Chicken Antiserum) B/Jiangxi-Xinjian/39/2008-like523.9% B/Jiangxi-Xinjian/39/2008- low* % China Recommended Epidemic Reference Strain for Network labs (2009 Oct-2010 Sept) In total 949 isolates(with Chicken Antiserum) B/Jiangxi-xiushui/32/2009-like % B/Jiangxi-xiushui/32/2009- low* % Antigenic Analysis of B(Victoria) –Tested at CNIC (Jan, 2009-July, 2009)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION *≥8 fold lower in HI titer B(Yamagata)NO.Percent WHO recommended Vaccine strain (2008South- 2009South) In total 115 isolates B/Florida/4/2006-like % B/Florida/4/2006-low* 65.2% China Recommended Epidemic Reference Strain for Network labs (2008Oct-2009Sept) In total 115 isolates B/Shanxi-beilin/127/2008-like % B/Shanxi-beilin/127/2008-low* % China Recommended Epidemic Reference Strain for Network labs (2007Oct-2008Sept) In total 115 isolates B/Fujian-Xinluo/54/2006-like % B/Fujian-Xinluo/54/2006-low* % China Recommended Epidemic Reference Strain for Network labs (2009Oct-2010Sept) In total 11 isolates B/Hubei-wujiagang/158/2009-like 11100% B/Hubei-wujiagang/158/2009- low* 00 Antigenic Analysis of B(Yamagata)–Tested at CNIC (Jan, 2009-July, 2009) (Chicken Antiserum)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Drug resistance surveillance for seasonal influenza (bioinformatics) ( Collection date from Jan2009 to July 2009) 39.0% (30/77) H1N1 viruses and 100% (49/49) H3N2 viruses isolated in mainland China from Jan2009 to July 2009 are resistant to adamantine. 61.0% (47/77) H1N1 viruses isolated in mainland China from Jan2009 to July 2009 are resistant to Oseltamivir. No Oseltamivir resistance viruses were found in H3N2(0/83) and B (0/49)viruses.

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Response to 2009 H1N1 Pandemic

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Support to Chinese Influenza Surveillance Network Special financial funds for Chinese Influenza Surveillance Network from Central finance Timely development of diagnostic method Enhanced Surveillance:  Expansion of network laboratories  Expansion of sentinel hospitals A series of trainings and meetings On site or by video/teleconference

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Diagnostic method development timeline

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Distribution of Diagnostic Kit to NISN and other countries/areas Country /areas RT PCR kits Real-time PCR kits Singapore5 Papua New Guinea5 Mongolia55 Cuba305 Macau10 Vietnam2 Laos2 Cambodia2 Brunei2 Indonesia2 Malaysia2 Philipine2 Thailand2 NISN in China Test for 45,200 specimens Test for 75,752 specimens

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Rapid information exchange

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION China-ASEAN workshop for Pandemic A(H1N1) 2009

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Illness onset date of the cases infected with the novel A(H1N1) influenza virus in Mainland China

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Geographic distribution of the cases infected with the novel A(H1N1) influenza virus

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Infection sources the cases infected with the novel A(H1N1) influenza virus in Mainland China

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Composition of the type/subtype of influenza virus since June1 st,2009 Pandemic A(H1N1) A(Unsubtyped) B(Unsubtyped)

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION HA Isolates from China Novel A(H1N1) Seasonal H1N1 MP NA NP NS PA PB1 PB2 Phylogenetic Analysis

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Drug Resistance Analysis by bioinformatics All the A(H1N1) viruses isolated in Mainland China are resistant to adamantine A/Hunan/SWL3/2009(H1N1) has a histamine to tyrosine mutation at residue 274 of the NA (N2 numbering; residue 275 by N1 numbering), which confers a high level of resistance to Oseltamivir. The case was imported case from US, and took Oseltamivir for prophylactic purpose 1~6 days before the onset of illness. The sequence was reported to Genebank. The other isolates are sensitive to Oseltamivir.

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION